IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis.

Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety

Franceschini, Franco;TINCANI, Angela;Cavazzana, Ilaria
2015-01-01

Abstract

Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis.
2015
THE JOURNAL OF RHEUMATOLOGY
2-s2.0-84923171309
WOS:000349032200011
Inglese
42
2
193-5
195
25512476
ABATACEPT; EFFICACY; RHEUMATOID ARTHRITIS; SAFETY; SUBCUTANEOUS FORMULATION; THERAPY
no
4
info:eu-repo/semantics/article
262
Reggia, Rossella; Franceschini, Franco; Tincani, Angela; Cavazzana, Ilaria
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11379/458130
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 15
social impact